Climb Bio price target raised to $19 from $8 at BTIG

BTIG raised the firm’s price target on Climb Bio (CLYM) to $19 from $8 and keeps a Buy rating on the shares. The company’s anti-CD19 mAb has multiple near-term data readouts across three indications, with a new SC formulation demonstrating 80% B-cell depletion comparable to IV dosing, offering added flexibility for future development, the analyst tells investors in a research note.